021-51111890
购物车（）
sales@molnova.cn
Apitegromab
CAS No. 2278276-46-1
Apitegromab ( —— )
产品货号. M36899 CAS No. 2278276-46-1
Apitegromab (SRK-015) 是一种抗肌生长抑制素单克隆抗体。Apitegromab 可用于包括脊髓性肌萎缩症在内的神经肌肉疾病的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥4722 | 有现货 |
|
| 10MG | ￥6536 | 有现货 |
|
| 25MG | ￥9179 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Apitegromab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Apitegromab (SRK-015) 是一种抗肌生长抑制素单克隆抗体。Apitegromab 可用于包括脊髓性肌萎缩症在内的神经肌肉疾病的研究。
-
产品描述Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Endocrinology/Hormones
-
靶点Opioid Receptor
-
受体Opioid Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number2278276-46-1
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Doreen Barrett, et al. A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy. Adv Ther. 2021 Jun;38(6):3203-3222. ?
产品手册
关联产品
-
EST73502
EST73502 是 μ-阿片受体 (Ki = 64 nM) 激动剂和 σ1 受体 (Ki = 118 nM) 拮抗剂。 EST73502 显示抗伤害活性。
-
Ac-RYYRIK-NH2
High affinity ligand for the NOP site (Ki = 1.5 nM). Antagonizes nociceptin-stimulated GTP binding in rat brain and the chronotropic effect of nociceptin on rat cardiomyocytes. However, displays potent agonist properties in vivo, inhibiting locomotor activity in mice.
-
[(pF)Phe4]Nociceptin...
Highly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotropic and feeding stimulation effects in vivo.
